DBF4 and prostate carcinoma: Because a primary goal of the screen was to identify genes whose mutation/deletion might mitigate response to PARPi therapy in CRPC patients, we examined publicly available prostate cancer genomic datasets for copy number loss of CDT1, CDC6, and DBF4 and whether these losses overlap with BRCA2 mutation status (35, 36).